Strategic biomarkers VDI Laboratory has a track record of developing and commercializing veterinary biomarkers, including NT-proBNP now marketed as CardioPet by IDEXX, and new biomarkers for canine/feline lymphoma, hemangiosarcoma, and sepsis. Sales opportunities exist in partnering with larger distributors or diagnostic players to co-market and broaden adoption of these biomarkers in clinics across the US and potential international expansion.

Clinical lab capabilities Operates Glycominds laboratory (CLIA certified) offering proprietary biomarkers for Multiple Sclerosis, indicating strong lab operations and regulated testing capabilities. Opportunities include contract research, clinical trial support, and high-complexity testing collaborations with veterinary and translational research organizations.

Growth through partnerships Past success with IDEXX suggests a business model centered on collaboration with major veterinary diagnostic companies. This presents a sales angle focused on licensing, co-development, or distribution partnerships to scale biomarker adoption and leverage established clinician networks.

Market readiness Current products are actively promoted in the US with multiple novel biomarkers in the pipeline, signaling a runway for market penetration in specialty veterinary diagnostics. Targeted outreach to veterinary hospitals, specialty clinics, and veterinary teaching hospitals could accelerate uptake and recurrent testing revenue.

Financial profiling Revenue is under one million dollars with a small team, indicating a lean operation ripe for strategic channel sales, partnerships, and channel enablement programs to drive scale. Business development efforts should emphasize joint go-to-market plans, reseller arrangements, and milestone-based partnerships to unlock growth while managing risk.